Kepler Gust, identified as a ten percent owner of Realloys Inc (EXCHANGE:ALOY), sold common shares of the company totaling $1.38 million, according to a Form 4 filing with the Securities and Exchange Commission.
The sales were executed in two separate trades at prices spanning $11.0072 to $12.3056 per share. Market data in the filing notes that the stock subsequently reached $13.75, up from a prior close of $11.25, despite a reported one-week decline of 18.5%. Over a longer horizon, shares have risen 271% in the past year, per InvestingPro data cited in the filing.
Transaction specifics disclosed on the Form 4 show that on March 13, 2026, Gust sold 49,000 shares at $12.3056 per share. Three days later, on March 16, 2026, Gust sold an additional 71,000 shares at $11.0072 per share. After these dispositions, the filing records that Gust directly holds 476,218 shares of Realloys Inc.
The filing also documents an earlier transfer on February 24, 2026, in which Gust sold 1,634,999 shares of Series A Convertible Preferred Stock for $1.00. Those preferred shares are convertible into common stock on a one-for-one basis.
Corporate financing and project updates
Separately, Realloys Inc has completed an underwritten public offering that raised $50 million through the sale of 2,702,702 shares of common stock at $18.50 per share. The company granted the underwriters a 30-day option to purchase up to an additional 396,963 shares. Company statements describe the capital raise as intended to support the company’s ongoing projects and expansions.
Among disclosed initiatives, Realloys announced plans to build a heavy rare earth metallization facility in Ohio, with operations targeted to begin between early and mid-2027. The project is estimated to cost approximately $40 million and is planned to produce about 30 tonnes of dysprosium metal and 15 tonnes of terbium metal each year.
On the technology front, Realloys demonstrated a new process for producing metallization-grade rare earth fluorides that does not use hydrofluoric acid. Independent laboratory testing, as noted by the company, confirmed the process meets industry standards, recording oxygen content below 1% by weight. The company characterized these developments as part of its strategic initiatives in both technological innovation and expansion of production capabilities.
Context and balance-sheet notes
The Form 4 disclosure and the company’s financing and operational announcements together outline recent liquidity events for both a significant shareholder and the company. The convertible preferred sale and the common-stock offering both have implications for potential future share counts, given the one-for-one conversion terms of the Series A preferred and the underwriters’ option. The company indicates the proceeds are earmarked to support projects already underway and planned expansions.
Details in the filings and company statements provide a factual record of insider sales, capital raising and the timeline and estimated cost for a new production facility, along with laboratory-validated technical results for a new fluoride production method.